MEDI0382 Phase IIb trial evaluates efficacy and safety in overweight and obese Type 2 Diabetes patients

Managing Type 2 Diabetes Mellitus (T2DM) often requires addressing both glycemic control and weight management, as obesity is a significant comorbidity and risk factor. Current standard-of-care treatments, while effective for glucose, may not sufficiently address weight or can even lead to weight gain. Novel therapeutic approaches are needed that can simultaneously improve glycemic control and promote weight loss, offering a more comprehensive solution for patients struggling with both conditions. Investigational compounds like MEDI0382 aim to fill this gap by exploring new mechanisms for metabolic improvement.

This was a Phase IIb, randomized, parallel, double-blind, placebo-controlled, and open-label active comparator study. A total of 834 overweight and obese subjects with Type 2 Diabetes Mellitus were enrolled. Participants were randomized to receive MEDI0382 at low, mid, or high doses via subcutaneous injection. The control arms included a placebo group and an active comparator arm receiving Liraglutide via subcutaneous injection. The primary objectives were to evaluate the efficacy and safety of MEDI0382 in this patient population, though specific endpoints were not detailed in the abstract.